Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naive Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial.

ABSTRACT:

Objectives

To evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO).

Design setting and patients

Phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals. Treatment-naïve patients with <6 month diagnosis of MO secondary to CRVO and best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016.

Intervention

Intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing.

Main outcomes

Mean change in BCVA after 12 months.

Results

24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2% male; median (IQR) time since diagnosis: 7

SUBMITTER: Garcia-Arumi J 

PROVIDER: S-EPMC6204200 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature